Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
July 27, 2020 DOI: 10.64239/pi-qt1701 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial |
|---|---|
| Population | Patients 65 or older |
| Interventions | Nasal esketamine antidepressant |
| Topics | Depression Esketamine |
| Key findings | Nasal esketamine did not outperform placebo in patients 65 or older when initiated with a new antidepressant. |
Abstract
Nasal esketamine did not outperform placebo in a randomized trial in patients 65 or older when initiated along with a new antidepressant.